Leuprolide Acetate for Central Precocious Puberty

"Eligibility for this particular research study depends on the child being between 2-11 years old. There are 13 similar studies for children and 63 for adults over the age of 65."

"Leuprolide Acetate (LA) is considered safe by our team at Power. We gave it a score of 3 because it is a Phase 3 trial, meaning that multiple rounds of testing have supported its efficacy and safety."

"45 patients that currently suffer from sexual precocity and meet the following additional criteria will be accepted into the trial: Children with CPP who are naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) (females 2 - 8 years of age, or males 2 - 9 years of age) or who have been on standard GnRHa therapy for at least 6 months (females 2 - 10 years of age, or males 2 - 11 years of age)., No history of clinically significant medical conditions or any other reason that the investigator determines would make the participant an unsuitable candidate"

"The primary goal of this trial, which will be measured over the course of 48 weeks, is to see the percentage of participants with suppressed luteinizing hormone (LH) levels (<4 mlU/mL). Additionally, the study hopes to observe the following secondary objectives: Part 1: The percentage of female participants with suppressed levels of estradiol to <20 pg/mL, Part 2: The percentage of participants with suppressed physical signs of puberty, and Part 2: The ratio of change from baseline in bone age vs chronological age."

"Leuprolide Acetate was first studied at SUNY Downstate Medical Center in 2004 and, since then, there have been a total of 141 clinical trials completed with 70 ongoing studies. A notable number of these studies are based out of Kansas City, Missouri."

"To minimize the impact on participants, this study is recruiting from 30 sites that are geographically dispersed. Currently, the study is looking for patients from locations including but not limited to Kansas City, Boston, and Tacoma."

"Leuprolide Acetate (LA) is most commonly used to treat advanced prostate cancer; however, it has also been show to be effective in managing anemia, central precocious puberty (cpp), and other conditions clinically similar to the aforementioned."

"Unfortunately, this particular trial is not currently looking for new patients. However, it is worth noting that the study was originally posted on October 24th, 2018 and was last edited on September 9th, 2022. Additionally, if you are interested in other studies, there are presently 9 clinical trials actively recruiting patients with sexual precocity and 70 studies for Leuprolide Acetate (LA) actively searching for participants."